2nd Quarter - Report

PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION for PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION

Firm
Client
Income
—
Expenses
$3,402,542
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, pharmacy networks, and mail-service pharmacy S.113 - Prescription Pricing for the People Act S.127 - Pharmacy Benefit Manager Transparency Act H.R.2679 - Pharmacy Benefits Manager Accountability Act H.R.2691 - Transparent PRICE Act H.R.3281 - Transparent PRICE Act S.1339 - Pharmacy Benefit Manager Reform Act H.R.3282 - Promoting Transparency and Health Competition in Medicare Act H.R.3561 - Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act S.1967 - Patients Before Middlemen (PBM) Act S.2052 - Protect Patient Access to Pharmacies Act S.1038 / H.R.1613 - Drug Price Transparency in Medicaid Act H.R.1770 - Equitable Community Access to Pharmacist Services Act S.1491 - Pharmacy and Medically Underserved Areas Enhancement Act H.R.3284 - Providers and Payers COMPETE Act Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration

LobbyistCovered position, as disclosed
KRISTIN A BASS —
JONATHAN M HEAFITZ —
LUCIA LEBENS New Deputy Chief of Staff, Sen. Norm Coleman (MN)
KATHERINE C. MURPHY —
JUAN CARLOS SCOTT —
JOCELYN WILES —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE; Executive Office of the President (EOP)

Bills named: H.R. 2691 (118th), H.R. 2679 (118th), H.R. 3561 (118th), H.R. 3281 (118th), H.R. 3284 (118th), S. 2052 (118th), S. 1967 (118th), S. 113 (118th), S. 1038 (118th), H.R. 3282 (118th), H.R. 1770 (118th), S. 1339 (118th), H.R. 1613 (118th), S. 127 (118th), S. 1491 (118th)

Medicare/Medicaid MMM

Issues related to prescription drug coverage and pharmacy benefits Regulatory and proposed legislative changes to Medicare Part D prescription drug benefits H.R.2666 -- Medicaid MVP for Patients Act S.652 / H.R.2630 -- Safe Step Act H.R.2679 -- Pharmacy Benefits Manager Accountability Act H.R.2691 - Transparent PRICE Act H.R.3281 - Transparent PRICE Act H.R.3282 - Promoting Transparency and Health Competition in Medicare Act H.R.3285 - Fairness for Patient Medications Act H.R.3561 - Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act S.1967 - Patients Before Middlemen (PBM) Act S.2052 - Protect Patient Access to Pharmacies Act S.2129 - Ensuring Access to Lower-Cost Medicines for Seniors Act H.R.4011 - Timely Access to Clinical Treatment Act S.1038 / H.R.1613 - Drug Price Transparency in Medicaid Act H.R.1770 - Equitable Community Access to Pharmacist Services Act S.1491 - Pharmacy and Medically Underserved Areas Enhancement Act S. 1375 / H.R.830 - Help Ensure Lower Patient (HELP) Copays Act H.R.1352 - Increasing Access to Biosimilars Act H.R.3799 - CHOICE Arrangement Act S.1130 - Health Care PRICE Transparency Act S.1131 - Drug Price Transparency Act H.R.3284 - Providers and Payers COMPETE Act Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration

LobbyistCovered position, as disclosed
KRISTIN A BASS —
JONATHAN M HEAFITZ —
LUCIA LEBENS New Deputy Chief of Staff, Sen. Norm Coleman (MN)
KATHERINE C. MURPHY —
JUAN CARLOS SCOTT —
JOCELYN WILES —

Contacted: Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Bills named: S. 1967 (118th), H.R. 1352 (118th), H.R. 4011 (118th), H.R. 3285 (118th), H.R. 3281 (118th), S. 2129 (118th), H.R. 2691 (118th), H.R. 3561 (118th), S. 2052 (118th), S. 1038 (118th), S. 652 (118th), H.R. 3284 (118th), H.R. 2679 (118th), S. 1375 (118th), S. 1130 (118th), H.R. 2630 (118th), H.R. 1770 (118th), H.R. 830 (118th), S. 1131 (118th), S. 1491 (118th), H.R. 3282 (118th), H.R. 1613 (118th), H.R. 2666 (118th), H.R. 3799 (118th)

Health Issues HCR

Issues related to prescription drug coverage and pharmacy benefits Issues related to the prescription drug marketplace, patents, and competition Regulatory and proposed legislative changes to Medicare Part D and Medicaid prescription drug benefits S.113 - Prescription Pricing for the People Act S.127 - Pharmacy Benefit Manager Transparency Act H.R.2666 - Medicaid MVP for Patients Act S.652 / H.R.2630 - Safe Step Act H.R.2679 - Pharmacy Benefits Manager Accountability Act H.R.2691 - Transparent PRICE Act H.R.3281 - Transparent PRICE Act S.1339 - Pharmacy Benefit Manager Reform Act S.1543 - A bill to require regulations concerning the disclosure of direct and indirect compensation from entities providing pharmacy benefit management services or third party administration services H.R.3282 - Promoting Transparency and Health Competition in Medicare Act H.R.3285 - Fairness for Patient Medications Act H.R.3561 - Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act S.1967 - Patients Before Middlemen (PBM) Act S.2052 - Protect Patient Access to Pharmacies Act S.2129 - Ensuring Access to Lower-Cost Medicines for Seniors Act H.R.4011 - Timely Access to Clinical Treatment Act S.1038 / H.R.1613 - Drug Price Transparency in Medicaid Act H.R.1770 - Equitable Community Access to Pharmacist Services Act S.1491 - Pharmacy and Medically Underserved Areas Enhancement Act S. 1375 / H.R.830 - Help Ensure Lower Patient (HELP) Copays Act S.954 / H.R.1488 - Affordable Insulin Now Act H.R.1503 - Prescription Information Modernization Act H.R.1352 - Increasing Access to Biosimilars Act S.1374 - Patient Right to Shop Act H.R.3799 - CHOICE Arrangement Act S.142 - Preserve Access to Affordable Generics and Biosimilars Act S.148 - Stop STALLING Act S.150 - Affordable Prescriptions for Patients Act S.574 - Increasing Prescription Drug Competition Act S.775 - Increasing Transparency in Generic Drug Applications Act H.R.1790 - Biologics Competition Act S.1067 - Ensuring Timely Access to Generics Act S.1114 - Expanding Access to Low-Cost Generics Act S.1120 - Improved Access to Affordable Medications Act S.1128 - Ensuring Access to Generic Medications Act S.1522 - A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable S.1130 - Health Care PRICE Transparency Act S.1131 - Drug Price Transparency Act H.R.3284 - Providers and Payers COMPETE Act Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation Implementation of Center for Medicare and Medicaid Services Final Rule, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Final Rule, CMS-4192-F, CMS-1744-F, provisions related to changes in Pharmacy Direct and Indirect Renumeration

LobbyistCovered position, as disclosed
KRISTIN A BASS —
JONATHAN M HEAFITZ —
LUCIA LEBENS New Deputy Chief of Staff, Sen. Norm Coleman (MN)
KATHERINE C. MURPHY —
JUAN CARLOS SCOTT —
JOCELYN WILES —

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP)

Bills named: S. 1967 (118th), H.R. 4011 (118th), S. 1130 (118th), S. 574 (118th), S. 1375 (118th), S. 1114 (118th), H.R. 3799 (118th), S. 1128 (118th), H.R. 3284 (118th), H.R. 1613 (118th), S. 1543 (118th), S. 1131 (118th), S. 1374 (118th), H.R. 1770 (118th), H.R. 3281 (118th), H.R. 1488 (118th), H.R. 830 (118th), S. 1120 (118th), H.R. 1503 (118th), S. 127 (118th), S. 1491 (118th), S. 1067 (118th), H.R. 2630 (118th), S. 2052 (118th), H.R. 2679 (118th), H.R. 3285 (118th), S. 1522 (118th), S. 1038 (118th), S. 150 (118th), H.R. 2666 (118th), S. 652 (118th), S. 142 (118th), H.R. 3561 (118th), S. 2129 (118th), S. 1339 (118th), S. 775 (118th), S. 954 (118th), S. 148 (118th), S. 113 (118th), H.R. 1352 (118th), H.R. 3282 (118th), H.R. 1790 (118th), H.R. 2691 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.